Short answer
MBX Biosciences, Inc. (MBX) filed an 8-K current report with the SEC on February 27, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 5.02 (Departure/Election of Directors or Officers). New lab/office lease signed Feb 24, 2026 in Burlington, MA: 13,642 sq ft; occupancy expected May 1, 2026.
MBX Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- New lab/office lease signed Feb 24, 2026 in Burlington, MA: 13,642 sq ft; occupancy expected May 1, 2026
- Rent-free for first 5 months post-commencement; base rent ~$68,200/month starting ~Oct 2026
- 4-year lease term; aggregate base rent ~$3.4M with ~3% annual escalations
- One-time 3-year extension option available; termination only permitted under breach or bankruptcy provisions
- Additional Rent (opex, taxes, utilities) owed on top of base rent: total occupancy cost will exceed $3.4M
Item 5.02 · Departure/Election of Directors or Officers
- CFO Richard Bartram resigning effective March 15, 2026; receives $13,400 COBRA lump sum plus severance per existing employment agreement
- Departure confirmed not due to dispute with company or auditors: reduces concern over financial reporting integrity issues
- Interim CFO John Smither (age 73) appointed March 16, 2026; part-time role at $325,000 base salary, 40% target bonus, $25,000 sign-on bonus
- Smither brings deep biotech CFO experience: Arcutis, Kite Pharma/Gilead integration, Sienna Biopharmaceuticals; former Ernst & Young audit partner
- Permanent CFO search underway: interim appointment signals transition risk; part-time structure may limit financial leadership capacity during search
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MBX Biosciences, Inc. 8-K filings
Get the next MBX 8-K as it lands
Follow MBX for push alerts, or ask the research agent what this filing means.